Bone Effects of Teriparatide Following Alendronate
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of 24 months of treatment with once daily
teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry
and architecture. Patients will include postmenopausal, osteoporotic women who have been
treated long term (at least 36 months) with alendronate, as well as postmenopausal,
osteoporotic women who have never been treated for osteoporosis.